Data may be delayed — last successful sync 2026-09-26 (19 days ago). Figures reflect the most recent completed ingest.
Company profile
Nurix Therapeutics, Inc.
NASDAQ: NRIX · Healthcare · Biotechnology
#369 of 1,417 Healthcare companies by revenuetop-quartile growth
EA Score
53DFH 51DQ 46GM 70SS 65
v0.1 · 65/100 weight · provisional
↑ market scale, Altman-Z · ↓ Piotroski F, disclosure history
Methodology →Revenue TTM
$36.8M
Rev growth YoY (TTM)
-58.4%
Net income (FY)
-$264.5M
Employees
317
as of 2026-09-10
Market cap
$2.7B
as of 2026-09-10
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$84.0M$84.0M2025
Net income-$264.5M-$264.5M2025
Operating income-$285.7M-$285.7M2025
Total assets$688.1M$688.1M2025
Liabilities$149.4M$149.4M2025
Equity$538.7M$538.7M2025
Revenue trend
FY2020 – FY2025 · USD
FY20
FY20
FY20
FY21
FY24
FY24
FY24
FY25
Revenue by segment
Filed disclosures · FY2025
By product
Collaboration Revenue64%
License Revenue36%
By geography
Not disclosed.
The read
What is Nurix Therapeutics, Inc.’s revenue?
Nurix Therapeutics, Inc. booked $84.0M in FY2025 revenue, growing 54% year over year — faster than most Healthcare companies we track, at a -314.9% net margin.
Peers · Healthcare
Delcath Systems, Inc.72B4D Molecular Therapeutics, Inc.58CARS Pharmaceuticals, Inc.41DIRadimed Corporation85AArcturus Therapeutics Holdings Inc.49DMeiraGTx Holdings plc48DNeighbors
San Mateo →Key facts
CEOArthur T. Sands
SectorHealthcare
IndustryBiotechnology
HeadquartersBrisbane, CA
ExchangeNASDAQ: NRIX
Employees317
IPO date2020-07-24
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.